Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter

Clin Cancer Res. 2021 Mar 1;27(5):1580. doi: 10.1158/1078-0432.CCR-20-2698.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms*
  • Mutation

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab